Skip to main content

Table 1 Baseline characteristics of patients before treatment with relugolix

From: Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study

 

Total (N = 17)

Age (years), median (IQR)

46.0 (43.0–48.0)

Parity, median (IQR)

1.0 (0.0–2.0)

BMI (kg/m2), median (IQR)

22.0 (20.5–26.2)

Menorrhagia, n (%)

17 (100)

Dysmenorrhea, n (%)

4 (24)

Hemoglobin (g/dL), median (IQR)

10.2 (7.9–10.6)

Diameter of leiomyomaa (mm), median (IQR)

39.0 (28.0–54.0)

Volume of leiomyomaa,b (cm3), median (IQR)

30.1 (10.8–55.9)

Leiomyoma protrusion ratea,c (%), median (IQR)

62.0 (49.0–69.0)

FIGO type of submucosal leiomyomaa, n (%)

 Type 0

2 (12)

 Type 1

11 (65)

 Type 2

4 (24)

Treatment periods (days), median (IQR)

126.0 (84.0–170.0)

  1. BMI, Body mass index, FIGO The international federation of gynecology and obstetrics, IQR Interquartile range
  2. aIn cases where patients had multiple leiomyomas, we evaluated the largest submucosal leiomyoma
  3. bThere were missing variables in the volume of leiomyoma (three patients) because they did not undergo magnetic resonance imaging
  4. cProtrusion rate of submucosal leiomyoma of FIGO type 1 or 2